Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OK-1 and Paclitaxel in Recurrent Endometrial Cancer
NCT07737795Phase 2Not yet recruiting
- Sponsor
- University of Oklahoma
- Start
- Aug 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of OK1 in endometrial cancer (EC), sponsored by University of Oklahoma. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
OK1
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT07737795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07737795.